Solid tumors research hub

A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.

This study is testing a new medicine, CLN-619, for people with advanced cancers like lung, cervical, or breast cancer. It's the first time this medicine is being given to people, either alone or with another drug called pembrolizumab, to see if it's safe and how much to give.

Electroporation for Cancer Treatment Real World Registry

This study looks at how well a treatment called electroporation works for skin and gut cancers in everyday life. It checks how often tumours shrink, if they come back, and any side effects people experience. It helps understand the long-term effects of this treatment.

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

This study looks at two drugs called dabrafenib and trametinib for various cancers with a specific gene change (BRAF V600). These drugs are already approved for some cancers and researchers want to see if they can help people with other rare cancers or cancers with this same change.

A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation